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Abstract
Background: Artemether/Lumefantrine (Coartem®) has been used as a first-line treatment for uncomplicated
Plasmodium falciparum infection since 2004 in Ethiopia. In the present study the therapeutic efficacy of artemether/
lumefantrine for the treatment of uncomplicated P. falciparum infection at Kersa, Jima zone, South-west Ethiopia,
has been assessed.
Methods: A 28 day therapeutic efficacy study was conducted between November 2007 and January 2008, in
accordance with the 2003 WHO guidelines. Outcomes were classified as early treatment failure (ETF), late clinical
failure (LCF), late parasitological failure (LPF) and adequate clinical and parasitological response (ACPR).
Results: 90 patients were enrolled and completed the 28 day follow-up period after treatment with artemether/
lumefantrine. Cure rate was very high, 96.3%, with 95% CI of 0.897-0.992 (PCR uncorrected). Age-stratified data
showed adequate clinical and parasitological response (ACPR) to be 100% for children under 5 and 97.4% and
87.3% for children aged 5-14, and adults, respectively. There was no early treatment failure (ETF) in all age groups.
Fever was significantly cleared on day 3 (P < 0.05) and 98% of parasites where cleared on day 1 and almost all
parasites were cleared on day 3. 72.5% of gametocytes were cleared on day 1, the remaining 27.5% of
gametocytes were maintained up to day 3 and total clearance was observed on day 7. Hemoglobin concentration
showed a slight increase with parasitic clearance (P > 0.05). No major side effect was observed in the study except
the occurrence of mouth ulcers in 7% of the patients.
Conclusions: The current study proved the excellent therapeutic efficacy of artemether/lumefantrine in the study
area and the value of using it. However, the proper dispensing and absorption of the drug need to be emphasized
in order to utilize the drug for a longer period of time. This study recommends further study on the toxicity of the
drug with particular emphasis on the development of oral ulcers in children.
Background
Early diagnosis and treatment of cases are the most
important strategies for the control and prevention of
malaria. It is crucial for proper management of the dis-
ease and to prevent further complications. P. falciparum
has developed resistance to nearly all antimalarials in
current use, although the geographical distribution of
resistance to any single antimalarial drug varies greatly
[1]. World maps that depict countries as having or not
having drug-resistant malaria are potentially misleading,
as there is great heterogeneity within countries and
across political boundaries [1].
In Ethiopia, the increased resistance of P. falciparum
to chloroquine (CQ) and sulfadoxine-pyrimethamine
(SP) necessitated a change as first-line antimalarial drug
for the treatment of P. falciparum. Consequently, Arte-
mether/Lumefantrine (Coartem®) (AL) was adopted in
2004 [2,3]. Currently Coartem® is being used as the
first-line drug for the treatment of uncomplicated
malaria [3]. A base-line study in 2004 [4] showed that
AL was a highly efficacious drug with a treatment suc-
cess of 99.1% and with no report of adverse effects [4].
However, the trend of malaria changes over time, and
thus the cure rate, tolerance, compliance and safety of
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emphasis to monitoring its therapeutic efficacy [2-5].
Therefore, close monitoring of resistance patterns would
be required to maximize the therapeutic benefits of this
drug as well as policy development and mapping of
resistance areas. Based on this notion, this study set the
objective to determine the efficacy of AL (Coartem®) in
the routine treatment of uncomplicated P. falciparum
malaria at Serbo health center, Kersa district, south west
Ethiopia.
Materials and methods
Study Area and Population
The study was conducted at Serbo Health Center, Kersa
district which is located in Jima zone, Oromia region,
323 km south west of Addis Ababa (Fig. 1) between
November 2007 and January 2008. The district is malar-
ious and covers 678.6 km square, with an altitude ran-
ging between 1600-2400 above sea level. Malaria is the
most prevalent seasonal disease in the area, accounting
for 77.1% of all the reported diseases in the health cen-
ter in 2006 and 2007. October to December is the peak
transmission season. Both P. vivax and P. falciparum
exist in the area with P. vivax prevailing all year, even in
non-transmission (relapse) seasons.
Study subjects
The study subjects were recruited from febrile patients
visiting Serbo Health Center based on WHO inclusion
guideline for the assessment and monitoring of antima-
larial drug efficacy for the treatment of uncomplicated
falciparum malaria [2].
Subject inclusion criteria
The following inclusion criteria were used for the study:
Mono-infection with P. falciparum, a parasitemia level
of 1000 - 100,000/μl, absence of danger signs or signs of
severe and complicated malaria according to the defini-
tion given by [2] presence of axillary temperature
(> 37.5°C), absence of other concomitant infections like
pneumonia which can cause fever, no use of antimalarial
drug two weeks prior to the study and compliance for
successive visits as per the protocol for uncomplicated
malaria recommendations.
Exclusion criteria
Patients with: (i) severe signs of malaria according to
WHO criteria, which included severe anaemia defined
by haemoglobin < 5 g/dl, (ii) history of allergic reactions
to the study drug Coartem® (iii) concomitant presence
of febrile condition with the potential to confound study
outcome (Example: acute respiratory infection (ARI),
measles, severe diarrhea, etc.) (iv) severe malnutrition
and (v) pregnant and lactating women were not
included in the study [2].
Sample collection
Finger-prick blood samples were collected from con-
senting patients for malaria parasite identification and
hemoglobin level measurement. Patients that satisfied
the criteria, were enrolled to the study and followed up
on days 1, 2, 3, 7, 14, 21, and 28 where finger-prick
samples were taken for microscopic glass slides. A paral-
lel drop of blood was collected on filter paper on day 0
during enrollment and on any unexpected visit. The fil-
ter paper was air dried and stored in a self sealing plas-
tic bag with desiccators for further molecular analysis.
Sample size
Considering the very low or unknown proportion of
clinical failure of artemether/lumefantrine resistance in
Ethiopia, sample size was calculated with 10% precision,
95% confidence interval, 15% withdrawal and 28 day
study period, 90 study participants were included in the
study [2].
Microscopic diagnosis
Thick and fixed thin blood smears were stained with
10% Giemsa (pH 7.4) for ten min. Blood films were
taken at least eight times for each patient during the
Figure 1 Map of Kersa district (Wereda), Oromia, Jima zone.
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unexpected visit by the patient. These smears were used
in species identification and thick blood films were used
to determine parasite density (100 high power field
(HPF) were the number of asexual parasites per HPF
were recorded, according to the method described in
the WHO Protocols [2-6]. A blood slide was considered
negative when no parasites were seen after examining
100 fields. Parasite count was based on the number of
asexual parasites observed against 200 leukocytes. This
number was then multiplied by 40 to gain an approxi-
mate count per microlitre.
No. parasites per l parasite count  wbc //   8000 200
Slides were read by two senior microscopists from the
Ethiopian Health and Nutrition Research Institute
(EHNRI) and one from Serbo health center. In case of
disagreement the majority result was taken. All slides
were properly documented for quality control.
Hemoglobin measurement
Finger-pick blood sample was used to measure hemo-
globin using a portable spectrophotometer (Haemocue).
Treatment and follow up schedule
Artemether-lumefantrine (Coartem®) was obtained from
Novartis pharma AG, Basel, Switzerland, Bach No.
T2005-59, through the WHO office, Addis Ababa. All
eligible patients were treated with Coartem® at day 0.
Dosing was a six dose regimen given twice daily for
three days. Study medication was administered based on
weight; the first dose was given under direct observa-
tion. The successive day’sd o s e sw e r eg i v e nt ot h e
patient/guardian for self administration in front of
health professionals in the area (Health extension work-
ers). Patients were followed for 30 min post treatment
and if vomiting occurred, a second full dose was admi-
nistered. If repeated vomiting occurred, patients were
withdrawn from the study. Patients were asked to return
to the clinic on days 1, 2, 3, 7, 14, 21, and 28 or were
highly encouraged to return whenever they did not feel
well. Patients, who failed to come to the clinic at the
scheduled time, were visited in their home on the same
day and the necessary blood sample, reports of adverse
effects and temperature data were collected.
Patient withdrawal
Patients were withdrawn from the study in case of (i)
vomiting the drug twice, (ii) withdrawal of consent, (iii)
onset of a serious febrile illness, (iv) intake of any drug
with antimalarial properties, (v) missing repeated treat-
ment doses, (vi) mixed species parasitemia or (vii) any
protocol violation. Patients who missed follow-up visits
and did not come on the successive day despite tracing
were considered as lost to follow-up. Patients withdrawn
and with complications were referred to the health
centers for proper treatment. Patients withdrawn for the
re-appearance of P. falciparum were treated with qui-
nine and those infected with P. vivax were treated with
chloroquine.
In vivo analysis and classification response
Patients were classified as early treatment failure (ETF),
late clinical failure (LCF), late parasitological failure
(LPF) or adequate clinical and parasitological response
(ACPR) as per WHO definitions [2].
ETF
Development of danger signs for severe malaria on Day
1, Day 2 or Day 3, in the presence of parasitemia; para-
sitemia on Day 2 higher than Day 0 count irrespective
of axillary temperature; parasitemia on Day 3 with axil-
lary temperature ≥ 37.5°C; parasitemia on Day 3 ≥ 25%
of count on Day 0.
LCF
Development of danger signs for severe malaria after
Day 3 in the presence of parasitemia, without previously
meeting any of the criteria of ETF. Presence of parasite-
mia and axillary temperature >37.5°C (or history of
fever) on any day from Day 4 to Day 28, without pre-
viously meeting any of the criteria of ETF.
LPF
Presence of parasitemia on any day from Day 7 to Day
28 and axillary temperature > 37.5°C, without previously
meeting any of the criteria of early treatment failure or
late clinical failure.
ACPR
Absence of parasitemia on Day 28 irrespective of axillary
temperature without previously meeting any of the cri-
teria of ETF, LTF or LPF.
Molecular analysis
Samples that were classified as ETF, LCF or LPF were
genotyped to differentiate recrudescence from re-infec-
tion. Blood samples for PCR were collected on standard
filter paper, air dried and stored in cool and dark boxes
with desiccants. Genotypic analysis was performed at
EHNRI as previously described for msp-1 [7] and msp-2
[8,9]. Cases in which pre- and post-treatment genotypes
were identical were considered as recrudescence; cases
in which pre- and post-genotypes were different were
considered as re-infection, mixed genotypes were classi-
fied as failures.
Ethical clearance
The study protocol was reviewed and approved by Ethi-
cal Review Committee of Ethiopian Health and Nutri-
tion Research Institute and Nation Ethical Review
Committee of Ethiopia.
Consent form
Prior to the trial, a consent form was signed by the
patient or by the parent/guardian after being translated
and read in the vernacular language that the patients or
the carers understood.
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All the data from recruited patients were imported into
an Excel spreadsheet and the WHO designed Excel data
analysis program was used for analysis and SPSS 11 were
used for descriptive statistics and comparing data [2].
Results
During the study, 1628 febrile cases, clinically suspected
to be infected with malaria, were screened for eligibility.
Of these 428 (26.3%) had malaria-positive slides and 361
( 2 2 . 2 % )o ft h e mh a dP. falciparum mono-infections. Of
the P. falciparum mono-infected patients, 236 could not
be enrolled in the study for having a parasite load below
1000 parasites per microliter of blood. Of the remaining
125 patients who were eligible for the study, 35 were
excluded for the following reasons: 27 were out of the
reachable area, 2 were pregnant, another 4 took anti-
malaria drugs before commencement of the study and
the remaining 2 refused consent.
Finally 90 patients fulfilled all the criteria and enrolled in
the study (Figure 2). Five were excluded for vomiting the
first dose twice and having mixed infection. On day 7, 85
slides from patients were examined and one person was
found to be P. falciparum positive and excluded as treat-
ment failure and treated with quinine. On day 21, 84 slides
were examined and two positive slides were found, one
positive for P. falciparum and the other for P. vivax.T h e
first was removed as treatment failure and the second
withdrawn from the study and treated with chloroquine.
On the final day (Day 28), slides from the remaining 82
patients were examined and one P. falciparum and three
P. vivax cases were recorded. The first was considered a
treatment failure and treated with quinine, and the later
three were taken as negative slides for data analysis and
were treated with chloroquine (Figure 2.)
The base-line characteristics of the 90 eligible patients
a r eg i v e ni nT a b l e1 .F o r t ye i g h t( 5 3 % )o ft h ep a t i e n t s
were females with 1.14 female to male ratio. The age
stratification showed 33 (37%) were under 5, 41 (46%)
between 5 and 14 and the remaining 16 (17.8%) were
adults (above 14). Auxiliary temperature was comparable
in the three age groups with mean of 38 ± 0.3°C at
enrollment. Paracetamol was given for all patients with
auxiliary temperature greater than or equal to 38°C.
1 P.f  positive on D7 
90 
Enrolled 
85 
Analyzed at D7 
5 
Excluded 
84 
Analyzed at D21 
82 
Analyzed at D28 
5 excluded
 4 mixed infection on D1 
  1 vomit 1
st dose twice 
84 
Analyzed at D14 
1 P.v and 1 P.f.  positive on D21 
1 P.v. D23 
1 P.f
3 P.v
77 Negative D28 
Figure 2 Details on study inclusion and follow up progress. P.f = P. falciparum; P.v = P. vivax.
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from 5.5 to 17.1 regardless of parasite load. Parasitic
load ranged from 1000-100,000 in all age groups and
the highest mean parasite density was observed in the 5-
14 age group followed by under 5 and adults. Gameto-
cytes at enrollment were observed in 6/90 (6.7%)
patients and declined with an increase in age, 9% in
under 5, 7.3% in 5-14 and none in adults.
In the present study 7.7%(7/90) patients (PCR uncor-
rected) were excluded during follow-up. And thus a
total 82 patients were analyzed at the end-point (day 28)
and the result was satisfactory compared with other stu-
dies. All patients completed the study properly and
none of them missed the follow-up.
C u r er a t ew a sv e r yh i g hi na l la g eg r o u p s( T a b l e2 ) .
The overall cure rate was 96.3% with 95% CI of 0.897-
0.992 (97.5% PCR corrected). ACPR was 100% in the
children under 5 and 97.4% (100% PCR corrected) and
87.3% in the 5-14 and adult groups, respectively. There
was no ETF in all age groups. There was one LCF
(1.2%), in the adult group and one LPF (PCR uncor-
rected) for each of the 5-14 and adult groups with the
overall rate of 2.4%. However, the overall rate reduced
to 1.2% as PCR adjustment ruled out one of the parasite
re-appearance in the 5-14 age group as re-infection.
As shown in Figure 3, fever clearance was similar in
all age groups, fever was significantly cleared on day 3
in all patients (P < 0.05). 98% of parasites were cleared
on day 1 and almost all parasites where cleared on day
3. In adults and 5-14 age groups, parasites were totally
cleared from blood on day 2 and 3, respectively. In
under 5 patients, a small fraction (1.1%) of patients
Table 1 Base line characteristics
< 5 years 5-14 years ≥ 15 years Total
n=3 3 n=4 1 n=1 6 n=9 0
Mean age (range) 2.8 (1-4.5) 9.1 (15-14) 21.3 (15-30) 9 (1-30)
Male 15 (45.5%) 20 (48.8%) 7 (43.8%) 42 (46.7%)
Weight(kg) 11.7 23.2 48.4 23.5
Temp (°C) 38.3(36.9-40.6) 38 (35.9-40.9) 38 (36.9-39) 38.1 (35.9-40.9)
Hemoglobin (g/dl) 11.13 (5.5-15.5) 12.5 (7.7-15.5) 13.6 (9.4-17.1) 12.2 (5.5-17.1)
Mean Parasite density per μl 18,983 32,607 5,541 22,660
Gametocyte carriage (n) 9% (3) 7.3%(3) 0% 6.7% (6)
Table 2 PCR corrected and uncorrected cure rate of day 28 analysis stratified by age
Under 5 (n = 33) 5-14(n = 41) Adult (>14)(n = 16) Total (n = 90)
No. % Prev.
PCR
uncorr.
% Prev.
PCR
corre.
No. % Prev.
PCR
uncorr.
No. % Prev.
PCR
corre.
No % Prev.
PCR
uncorr.
%Prev.
PCR
corre.
No. %Prev.
PCR
uncorr.
No. % Prev.
PCR
corre.
ETF 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0
LCF 0 0.0 0.0 0 0.0 0 0.0 1 6.3 6.3 1 1.2 1 1.2
LPF 0 0.0 0.0 1 2.6 0 0.0 1 6.3 6.3 2 2.4 1 1.2
ACPR 28 100.0 100.0 37 97.4 37 100.0 14 87.3 87.3 79 96.3 79 97.5
Total Analysis 28 38 37 16 82 81
With. 5 340 89
Loss 0 15.2 15.2 0 7.3 0 9.8 0 0.0 0.0 8.9 0 100.0
Total 33 41 41 16 90 90
ETF: Early treatment failure
LCF: Late clinical failure
LPF: Late parasitological failure
ACPR: Adequate clinical and parasitological response
With: withdrew
Prev: Prevalence
Corre: corrected
Uncorr: Uncorrected
No: Number
%: percent
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occurred on Day 7 (Table 3).
Gametocyte clearance declined with age in the early
treatment days, 72.5% were cleared on day 1. However,
the remaining, about 28% of gametocyte load was main-
tained up to day 3 irrespective of treatment. However,
total clearance was observed on day 7 (Figure 4).
Hemoglobin concentration showed a slight increase
with parasitic clearance from the blood, however, the
mean change in hemoglobin concentration was not sta-
tistically significant between day 0, day 14 and day 28 (P
> 0.05) (Table 4). Although improvement was observed
in hemoglobin concentration with decline in parasite
density, the correlation between the two was statistically
insignificant (p = 0.132).
Overall, there were 255 adverse events reported upon
taking the drug (data not shown) of which the most
common ones were cough in 46% of cases, headache in
17%, anorexia in 9%, weakness/fatigue in 7%, abdominal
pain in 5%, diarrhea and sleep disorder in 3%, and
vomiting in 2% of the cases. There was also a
considerable occurrence of inflammation of the oral
mucosa (mouth ulcer) in 7% of patients.
Most of adverse events disappeared with resolution of
the disease, however cough prevailed after treatment.
The occurrence of mouth ulcer (peri-oral wound) is not
a commonly reported adverse effect of Coartem®, how-
ever, it was recorded in considerable number of patients
(7%) in under 5 and 5-14 age groups.
Discussion
Our findings have indicated that artemether/lumefantrine
(Coartem®) has a high cure rate. The results showed very
high efficacy in the very young children less than five
years of age followed by middle age children and adults.
Results from the present study were consistent with pre-
vious studies conducted in Ethiopia and elsewhere
[4,10-16]. The overall cure rate was 96.3% (97.5% PCR
corrected). Although the results obtained in the present
study are similar to the results of a study conducted in
Uganda [15] the age-stratified results from Uganda
showed a reversed trend i.e., 100%, 97.7% and 96.4% cure
rates were obtained for adults, 5-14 and under five, age
groups, respectively. This may be due to differences in
m a l a r i ae x p o s u r e ,w h e r ea d u l t si nm o r ee n d e m i ca r e a s
acquire immunity to enhance the drug effect.
Inclusion of all age groups in the trial was because the
area showed unstable malaria of lower (hypo) endemi-
city where inhabitants were considered to be non-
immune to malaria. In accord with this, the child sple-
nomegally rate of the district was found to be 7.3%
(data not shown) confirming the hypo-endemicity of the
s t u d ys i t e .H e n c eo u rs t u d ya r e ab e i n go n eo fa n
unstable seasonal malarious type, no such stratified
immunity acquisition was expected. However, the high
cure rate among children could be due to higher milk/
fat content in their diet, which facilitates the absorption
and hence efficacy of Coartem®. This is actually a known
Table 3 Summary of the average body temperature (°C),
and parasite load (μl) stratified by age.
Under 5 (n = 33) 5-14 (n = 41) Adults (n = 16)
Day Temp Para Temp Para Temp Para
D0 38.3 18983 38 32607 37.9 5541
D1 37.4 350.2 37 676 37 102
D2 37.3 13.3 36.6 59.8 36.5 0
D3 37 1.1 36.6 0 36.7 0
D7 36.9 0 36.5 0 36.4 0
D14 37 0 36.4 0 36.6 0
D21 36.9 0 36.5 0 36.3 0
D28 37 0 36.5 0 36.4 0
Temp: Temperature
Para: parasite load (μl)
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Figure 3 Summary of the average body temperature (°C) and parasite density (μl) over the study period.
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the oral route [17]). Nevertheless, the age differences in
cure rate were low.
Of the total of the three treatment failures (one LPF
and two LCFs), PCR genotyping showed two of the
three recurrent infections (one LPF and one LCF) were
recrudescence and one of the LCF was PCR unresolved
and excluded. The PCR analysis result increased the
overall efficacy in to 97.5%, and the recrudescence rate
with Coartem® was found to be very low at about 2.5%.
In this study, although Coartem® clears fever and para-
sitemia in a very short period of time (less than three
days), the concentration of hemoglobin fails to increase
within the same period of time. Increments in hemoglo-
bin level have been noted with clearance of fever and
parasitemia, especially in those patients who had a lower
level of hemoglobin concentration in the baseline of
treatment than others. However, the difference was sta-
tistically insignificant (p < 0.05). Similar findings were
also observed in other studies [10,14]. The high preva-
lence of geohelminths (especially hookworm) in the area
can also be a contributing factor to the chronicity of
anemia. A recent study in Asendabo, one of the nearby
districts of Jima zone, showed 27.6% (102/370) of the
sample population to be anemic, of which, 26.5% (27/
102) had hookworm infection, 19.6% (20/102) were
malaria positive and 15.8% (19/102) were physiologically
anemic with no infection and 22.5% with co-infection.
Anemia was significantly higher in hookworm positive
individuals [18].
Fever is a manifestation of malaria that most fre-
quently causes discomfort. Thus, it was encouraging
that patients treated with Coartem® become afebrile
within the first two or three days. An antipyretic
(paracetamol) was given for febrile patients (body
temperature above 38°C), however the number of
patients who required paracetamol during the follow
up period was significantly low compared to the base-
line. A similar finding was noted in other studies
[4,10-15,17,19]. This is due to the inherent feature of
Coartem®, as a drug with fast resolution capacity of
clinical symptoms.
The study showed the decline of gametocytes with
treatment. They were almost cleared from the patients
after seven days. This rate of clearance was higher when
compared with other studies, which reported the pre-
sence of gametocytes up to the 14
th day and beyond
[19,14]. It has been reported that artemesinin derivatives
are gametocidal [10,20,21] and the absence of gameto-
cytes, seven days post treatment with Coartem® supports
the report that there was some effect of the artemisinin
derivative on the sexual stage of the parasite [21]. Other
aretemesinin combinations (ACTs) were also reported
to have the same effect [18,14]. Coartem® decreases
gametocytes by 6-8 fold compared with SP and CQ [21].
Thus, the present finding is in line with other studies.
In other studies, Coartem® was reported to reduce
gametocyte infectivity down to 40% [21] of paramount
importance in the control of transmission compared
with other drugs.
Studies showed that the overall toxicity of artemether
combinations is very low, the drug is well-tolerated and
non-compliance is very low [11,17,21]. A number of
side effects were seen for Coartem® most of which are
Figure 4 Gametocytemia after treatment.
Table 4 Summary of the average hemoglobin
concentration (mg/dl) stratified by age.
Days/Age Under 5
(n = 33)
5-14
(n = 41)
Adults
(n = 16)
Hb Hb Hb
D0 11.13 12.5 13.6
D14 11.6 12.2 13.3
D28 11.7 12.8 13.9
P Value > 0.05 > 0.05 > 0.05
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effect noted in 16.5% of all patients was dry, unproduc-
tive cough at baseline. This appears to be very likely a
symptom associated with the disease. Interestingly, a
further 45% of all patients developed this symptom after
commencement of treatment. Similar results were
reported in a study conducted in Uganda where, 37%
and 40% of cough was observed before and after treat-
ment, respectively [13]. However cough, headache,
abdominal pain and anorexia were the most common
pro-dromal complaints reported. In addition, the present
study revealed the development of oral inflamation (oral
ulcer) with improved clinical and parasitological signs,
indicating that it is not hyper-pyrexia induced phenom-
ena. To the best of our knowledge these side effect has
not been reported for Coartem® and its etiology is not
clear. Low levels of immunity due to concurrent diseases
such as HIV could be one reason. But, the problem has
been noted in 7.1% (6/85) of the patients. The clinicians
in the area have also reported the same side effect of
the drug in the past. It is therefore, very unlikely to con-
sider the occurrence to be due to chance.
Conclusion and Recommendation
This study has proved the excellent therapeutic efficacy
profile of the combination drug, given as a three day
multiple regimen of the optimized formulation for the
treatment of P. falciparum in Kersa district south west,
Ethiopia. Four years after its introduction as a first line
drug, Coartem® has been proved to be effective, in
rapidly clearing fever and parasites within 72 h in
patients suffering from uncomplicated malaria. However,
the proper absorption of the drug must be ensured and
monitored through controlled nutritional interventions
so that the parasites are not exposed to mal-absorbed
low, tolerable level of the drug.
This work also recommends further study on blood
concentration of the drug and pharmaco-vigilance on
the drug toxicity particularly the development of mouth
ulcer in children, as drug adverse effects hamper com-
pliance to the proper dosage which in turn enhances
development of drug resistance.
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